Literature DB >> 32259446

Molecule Property Analyses of Active Compounds for Mycobacterium tuberculosis.

Vadim Makarov1, Elena Salina1, Robert C Reynolds2, Phyo Phyo Kyaw Zin3,4, Sean Ekins5.   

Abstract

Tuberculosis (TB) continues to claim the lives of around 1.7 million people per year. Most concerning are the reports of multidrug drug resistance. Paradoxically, this global health pandemic is demanding new therapies when resources and interest are waning. However, continued tuberculosis drug discovery is critical to address the global health need and burgeoning multidrug resistance. Many diverse classes of antitubercular compounds have been identified with activity in vitro and in vivo. Our analyses of over 100 active leads are representative of thousands of active compounds generated over the past decade, suggests that they come from few chemical classes or natural product sources. We are therefore repeatedly identifying compounds that are similar to those that preceded them. Our molecule-centered cheminformatics analyses point to the need to dramatically increase the diversity of chemical libraries tested and get outside of the historic Mtb property space if we are to generate novel improved antitubercular leads.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32259446      PMCID: PMC7702311          DOI: 10.1021/acs.jmedchem.9b02075

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  230 in total

1.  Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients.

Authors:  Andreas H Diacon; Rodney Dawson; Madeleine Hanekom; Kim Narunsky; Stefan J Maritz; Amour Venter; Peter R Donald; Christo van Niekerk; Karl Whitney; Doris J Rouse; Martino W Laurenzi; Ann M Ginsberg; Melvin K Spigelman
Journal:  Antimicrob Agents Chemother       Date:  2010-05-24       Impact factor: 5.191

2.  Synthesis, tuberculosis inhibitory activity, and SAR study of N-substituted-phenyl-1,2,3-triazole derivatives.

Authors:  Marilia S Costa; Núbia Boechat; Erica A Rangel; Fernando de C da Silva; Alessandra M T de Souza; Carlos R Rodrigues; Helena C Castro; Ivan N Junior; Maria Cristina S Lourenço; Solange M S V Wardell; Vitor F Ferreira
Journal:  Bioorg Med Chem       Date:  2006-09-01       Impact factor: 3.641

Review 3.  The tuberculosis drug discovery and development pipeline and emerging drug targets.

Authors:  Khisimuzi Mdluli; Takushi Kaneko; Anna Upton
Journal:  Cold Spring Harb Perspect Med       Date:  2015-01-29       Impact factor: 6.915

4.  Easy-To-Synthesize Spirocyclic Compounds Possess Remarkable in Vivo Activity against Mycobacterium tuberculosis.

Authors:  Ana Guardia; Jessica Baiget; Mónica Cacho; Arancha Pérez; Montserrat Ortega-Guerra; Winston Nxumalo; Setshaba D Khanye; Joaquín Rullas; Fátima Ortega; Elena Jiménez; Esther Pérez-Herrán; María Teresa Fraile-Gabaldón; Jorge Esquivias; Raquel Fernández; Esther Porras-De Francisco; Lourdes Encinas; Marta Alonso; Ilaria Giordano; Cristina Rivero; Juan Miguel-Siles; Javier G Osende; Katrina A Badiola; Peter J Rutledge; Matthew H Todd; Modesto Remuiñán; Carlos Alemparte
Journal:  J Med Chem       Date:  2018-12-12       Impact factor: 7.446

5.  A regio- and stereoselective 1,3-dipolar cycloaddition for the synthesis of new-fangled dispiropyrrolothiazoles as antimycobacterial agents.

Authors:  Abdulrahman I Almansour; Sadath Ali; Mohamed Ashraf Ali; Rusli Ismail; Tan Soo Choon; Velmurugan Sellappan; Karthi Keyan Elumalai; Suresh Pandian
Journal:  Bioorg Med Chem Lett       Date:  2012-10-22       Impact factor: 2.823

Review 6.  Antimycobacterial activities of riminophenazines.

Authors:  V M Reddy; J F O'Sullivan; P R Gangadharam
Journal:  J Antimicrob Chemother       Date:  1999-05       Impact factor: 5.790

7.  Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model.

Authors:  K N Williams; C K Stover; T Zhu; R Tasneen; S Tyagi; J H Grosset; E Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

8.  Diarylquinolines target subunit c of mycobacterial ATP synthase.

Authors:  Anil Koul; Najoua Dendouga; Karen Vergauwen; Brenda Molenberghs; Luc Vranckx; Rudy Willebrords; Zorica Ristic; Holger Lill; Ismet Dorange; Jerome Guillemont; Dirk Bald; Koen Andries
Journal:  Nat Chem Biol       Date:  2007-05-13       Impact factor: 15.040

9.  Structure-Based Design of MptpB Inhibitors That Reduce Multidrug-Resistant Mycobacterium tuberculosis Survival and Infection Burden in Vivo.

Authors:  Clare F Vickers; Ana P G Silva; Ajanta Chakraborty; Paulina Fernandez; Natalia Kurepina; Charis Saville; Yandi Naranjo; Miquel Pons; Laura S Schnettger; Maximiliano G Gutierrez; Steven Park; Barry N Kreiswith; David S Perlin; Eric J Thomas; Jennifer S Cavet; Lydia Tabernero
Journal:  J Med Chem       Date:  2018-09-10       Impact factor: 7.446

10.  Acquired Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis.

Authors:  Guido V Bloemberg; Peter M Keller; David Stucki; David Stuckia; Andrej Trauner; Sonia Borrell; Tsogyal Latshang; Mireia Coscolla; Thomas Rothe; Rico Hömke; Claudia Ritter; Julia Feldmann; Bettina Schulthess; Sebastien Gagneux; Erik C Böttger
Journal:  N Engl J Med       Date:  2015-11-12       Impact factor: 91.245

View more
  8 in total

1.  Heterologous Expression of ethA and katG in Mycobacterium marinum Enables the Rapid Identification of New Prodrugs Active against Mycobacterium tuberculosis.

Authors:  Vien Q T Ho; Theo Verboom; Mark K Rong; Eva Habjan; Wilbert Bitter; Alexander Speer
Journal:  Antimicrob Agents Chemother       Date:  2021-03-18       Impact factor: 5.191

2.  Novel Antibacterial Activity of Febuxostat, an FDA-Approved Antigout Drug against Mycobacterium tuberculosis Infection.

Authors:  Lee-Han Kim; Soon Myung Kang; Jake Whang; Kee Woong Kwon; Sung Jae Shin
Journal:  Antimicrob Agents Chemother       Date:  2022-08-30       Impact factor: 5.938

3.  Machine Learning Models for Mycobacterium tuberculosis In Vitro Activity: Prediction and Target Visualization.

Authors:  Thomas R Lane; Fabio Urbina; Laura Rank; Jacob Gerlach; Olga Riabova; Alexander Lepioshkin; Elena Kazakova; Anthony Vocat; Valery Tkachenko; Stewart Cole; Vadim Makarov; Sean Ekins
Journal:  Mol Pharm       Date:  2021-12-29       Impact factor: 5.364

Review 4.  Potential therapeutic targets from Mycobacterium abscessus (Mab): recently reported efforts towards the discovery of novel antibacterial agents to treat Mab infections.

Authors:  William Addison; Martyn Frederickson; Anthony G Coyne; Chris Abell
Journal:  RSC Med Chem       Date:  2022-03-10

5.  Computational Approaches to Identify Molecules Binding to Mycobacterium tuberculosis KasA.

Authors:  Ana C Puhl; Thomas R Lane; Patricia A Vignaux; Kimberley M Zorn; Glenn C Capodagli; Matthew B Neiditch; Joel S Freundlich; Sean Ekins
Journal:  ACS Omega       Date:  2020-11-15

Review 6.  Analogues of Pyrimidine Nucleosides as Mycobacteria Growth Inhibitors.

Authors:  Liudmila A Alexandrova; Anastasia L Khandazhinskaya; Elena S Matyugina; Dmitriy A Makarov; Sergey N Kochetkov
Journal:  Microorganisms       Date:  2022-06-27

7.  Hydroxylation of Antitubercular Drug Candidate, SQ109, by Mycobacterial Cytochrome P450.

Authors:  Sergey Bukhdruker; Tatsiana Varaksa; Irina Grabovec; Egor Marin; Polina Shabunya; Maria Kadukova; Sergei Grudinin; Anton Kavaleuski; Anastasiia Gusach; Andrei Gilep; Valentin Borshchevskiy; Natallia Strushkevich
Journal:  Int J Mol Sci       Date:  2020-10-16       Impact factor: 5.923

Review 8.  Physicochemical properties and Mycobacterium tuberculosis transporters: keys to efficacious antitubercular drugs?

Authors:  Elizabeth Fullam; Robert J Young
Journal:  RSC Med Chem       Date:  2020-12-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.